Bleeding time and antiplatelet agents in normal volunteers

E. M. Pogliani, C. Fowst, R. Bregani, G. Corneo

Research output: Contribution to journalArticle

Abstract

Clinical trials have shown that antiplatelet agents are effective in the prevention of thrombosis in arterial diseases and increase bleeding time. To compare the effects of three such drugs [acetylsalicylic acid (ASA) at two dose levels, ticlopidine and indobufen] on bleeding time, we performed a randomized cross-over study on 12 normal subjects. All received the four treatments (ASA 300 mg daily and 500 mg twice daily, ticlopidine 250 mg twice daily and indobufen 200 mg twice daily, each for 6 days plus one dose on day 7) in a sequential manner with a washout period of 15 days between the treatments. Bleeding time was measured using a Surgicut device (Ortho, Milan, Italy) before treatment, 2 and 24 h after the first administration, and before and 2, 24, 48 and 72 h after the last administration. ASA (at both doses) and indobufen quickly induced a significant prolongation of bleeding time, but the effect of indobufen soon wore off after the treatment was stopped, unlike that of ASA. In contrast, ticlopidine treatment prolonged bleeding time only after the first 24 h, and after 7 days the mean value was significantly higher than with ASA (both doses) and indobufen. This significant difference in bleeding time between ticlopidine and the other drugs was still present 48 h after the end of treatment.

Original languageEnglish
Pages (from-to)58-61
Number of pages4
JournalInternational Journal of Clinical & Laboratory Research
Volume22
Issue number1-4
DOIs
Publication statusPublished - Mar 1992

Fingerprint

Bleeding Time
Platelet Aggregation Inhibitors
Ticlopidine
Aspirin
Healthy Volunteers
Therapeutics
Pharmaceutical Preparations
Cross-Over Studies
Italy
Wear of materials
indobufen
Thrombosis
Clinical Trials
Equipment and Supplies

Keywords

  • Acetylsalicylic acid
  • Antiplatelet agents
  • Bleeding time
  • Indobufen
  • Ticlopidine

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Bleeding time and antiplatelet agents in normal volunteers. / Pogliani, E. M.; Fowst, C.; Bregani, R.; Corneo, G.

In: International Journal of Clinical & Laboratory Research, Vol. 22, No. 1-4, 03.1992, p. 58-61.

Research output: Contribution to journalArticle

Pogliani, E. M. ; Fowst, C. ; Bregani, R. ; Corneo, G. / Bleeding time and antiplatelet agents in normal volunteers. In: International Journal of Clinical & Laboratory Research. 1992 ; Vol. 22, No. 1-4. pp. 58-61.
@article{42c6c91cf8ee4a1fbb805acac7abfcc1,
title = "Bleeding time and antiplatelet agents in normal volunteers",
abstract = "Clinical trials have shown that antiplatelet agents are effective in the prevention of thrombosis in arterial diseases and increase bleeding time. To compare the effects of three such drugs [acetylsalicylic acid (ASA) at two dose levels, ticlopidine and indobufen] on bleeding time, we performed a randomized cross-over study on 12 normal subjects. All received the four treatments (ASA 300 mg daily and 500 mg twice daily, ticlopidine 250 mg twice daily and indobufen 200 mg twice daily, each for 6 days plus one dose on day 7) in a sequential manner with a washout period of 15 days between the treatments. Bleeding time was measured using a Surgicut device (Ortho, Milan, Italy) before treatment, 2 and 24 h after the first administration, and before and 2, 24, 48 and 72 h after the last administration. ASA (at both doses) and indobufen quickly induced a significant prolongation of bleeding time, but the effect of indobufen soon wore off after the treatment was stopped, unlike that of ASA. In contrast, ticlopidine treatment prolonged bleeding time only after the first 24 h, and after 7 days the mean value was significantly higher than with ASA (both doses) and indobufen. This significant difference in bleeding time between ticlopidine and the other drugs was still present 48 h after the end of treatment.",
keywords = "Acetylsalicylic acid, Antiplatelet agents, Bleeding time, Indobufen, Ticlopidine",
author = "Pogliani, {E. M.} and C. Fowst and R. Bregani and G. Corneo",
year = "1992",
month = "3",
doi = "10.1007/BF02591396",
language = "English",
volume = "22",
pages = "58--61",
journal = "Ricerca in Clinica e in Laboratorio",
issn = "0940-5437",
publisher = "Springer Verlag",
number = "1-4",

}

TY - JOUR

T1 - Bleeding time and antiplatelet agents in normal volunteers

AU - Pogliani, E. M.

AU - Fowst, C.

AU - Bregani, R.

AU - Corneo, G.

PY - 1992/3

Y1 - 1992/3

N2 - Clinical trials have shown that antiplatelet agents are effective in the prevention of thrombosis in arterial diseases and increase bleeding time. To compare the effects of three such drugs [acetylsalicylic acid (ASA) at two dose levels, ticlopidine and indobufen] on bleeding time, we performed a randomized cross-over study on 12 normal subjects. All received the four treatments (ASA 300 mg daily and 500 mg twice daily, ticlopidine 250 mg twice daily and indobufen 200 mg twice daily, each for 6 days plus one dose on day 7) in a sequential manner with a washout period of 15 days between the treatments. Bleeding time was measured using a Surgicut device (Ortho, Milan, Italy) before treatment, 2 and 24 h after the first administration, and before and 2, 24, 48 and 72 h after the last administration. ASA (at both doses) and indobufen quickly induced a significant prolongation of bleeding time, but the effect of indobufen soon wore off after the treatment was stopped, unlike that of ASA. In contrast, ticlopidine treatment prolonged bleeding time only after the first 24 h, and after 7 days the mean value was significantly higher than with ASA (both doses) and indobufen. This significant difference in bleeding time between ticlopidine and the other drugs was still present 48 h after the end of treatment.

AB - Clinical trials have shown that antiplatelet agents are effective in the prevention of thrombosis in arterial diseases and increase bleeding time. To compare the effects of three such drugs [acetylsalicylic acid (ASA) at two dose levels, ticlopidine and indobufen] on bleeding time, we performed a randomized cross-over study on 12 normal subjects. All received the four treatments (ASA 300 mg daily and 500 mg twice daily, ticlopidine 250 mg twice daily and indobufen 200 mg twice daily, each for 6 days plus one dose on day 7) in a sequential manner with a washout period of 15 days between the treatments. Bleeding time was measured using a Surgicut device (Ortho, Milan, Italy) before treatment, 2 and 24 h after the first administration, and before and 2, 24, 48 and 72 h after the last administration. ASA (at both doses) and indobufen quickly induced a significant prolongation of bleeding time, but the effect of indobufen soon wore off after the treatment was stopped, unlike that of ASA. In contrast, ticlopidine treatment prolonged bleeding time only after the first 24 h, and after 7 days the mean value was significantly higher than with ASA (both doses) and indobufen. This significant difference in bleeding time between ticlopidine and the other drugs was still present 48 h after the end of treatment.

KW - Acetylsalicylic acid

KW - Antiplatelet agents

KW - Bleeding time

KW - Indobufen

KW - Ticlopidine

UR - http://www.scopus.com/inward/record.url?scp=0026493266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026493266&partnerID=8YFLogxK

U2 - 10.1007/BF02591396

DO - 10.1007/BF02591396

M3 - Article

C2 - 1633323

AN - SCOPUS:0026493266

VL - 22

SP - 58

EP - 61

JO - Ricerca in Clinica e in Laboratorio

JF - Ricerca in Clinica e in Laboratorio

SN - 0940-5437

IS - 1-4

ER -